You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb and 360Dx.
The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.
The 20-minute PCR-based test had near complete agreement with lab-based testing.
The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.
In a conversation at the Association for Molecular Pathology meeting, the directors touched on topics such as test allocation and staffing and reagent shortages.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
A recent study showed that a method called affine transformation can be used to increase the number of true positive qPCR samples detected.
The initiative will build up pathogen sequencing capacity through investment from the Gates Foundation, Microsoft, Illumina, and Oxford Nanopore.
European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.
Science reports that Science Foundation Ireland is seeking annual budget increases.
According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.
In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.